Resistant Hypertension Treatment Market to Receive Overwhelming Hike in Revenues by 2024

Global Resistant Hypertension Treatment Market: Overview
Hypertension is one of the common untreated diseases and poses major risk for heart failure, renal failure, cerebrovascular disease, cardiovascular disease, and coronary heart disease. About less than half of hypertensive patients in the U.S. are using economical generic antihypertensive drugs (AHDs). About 5%-10% (maximum to 20%-30%) of hypertensive patients with incompetently controlled hypertension have resistant hypertension. Resistant hypertension is a condition when the blood pressure remains higher than the normal range despite optimum dosage of three antihypertensive drugs, including a diuretics. Resistant hypertension includes patients whose blood pressure controlled on ≥ 4 antihypertensive drugs, but excludes those with uncontrolled blood pressure on

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=41111

Global Resistant Hypertension Treatment Market: Drivers and Restraints

Resistant hypertension is different from uncontrolled hypertension. For a precise identification of prevalence of resistant hypertension, a compulsory titration study of a large and diverse hypertensive group is required. Resistant hypertension denotes a risky phenotype. Genetic factors play a more crucial role in resistant hypertension as compared to general hypertension. Although for resistant hypertensive patients, genetic valuations are limited. In one of the limited genetic assessments of patients in Finland, investigators screened 347 patients with resistant hypertension who had mutation on the γ and β subunits of the epithelial sodium channel.
Mutation on the γ and β subunits can cause Liddle’s syndrome. Liddle’s syndrome is a rare form of hypertension (monogenic). According to data collected by the National Health and Nutrition Examination Survey (NHANES) from its study of samples of non-institutionalized, adult, civilian population, the prevalence rate of resistant hypertension was estimated around 8.9?±?0.6% among the population of the U.S. during 2003 to 2008. The study suggests that resistant hypertension and hypertension have become wide-spread due to increase of obesity among the general population and growth in geriatric population. Resistant hypertension is more prevalent among the non-black Hispanic or African America, male, obese, and elderly population. The global resistant hypertension treatment market has been expanding over the years. Growth in geriatric population is a major factor boosting the resistant hypertension treatment market. Increase in consumption of alcohols, junk foods, etc. is another key driver of the resistant hypertension treatment market. However, ignorance and drug resistance are the main restraints of the resistant hypertension treatment market.
Request a Sample of Resistant Hypertension Treatment Market: https://www.transparencymarketresearch.com/checkout.php?rep_id=41111<ype=S
Global Resistant Hypertension Treatment Market: Key Segments

The global resistant hypertension treatment market can be segmented based on type of treatment, end-user, and region. In terms of type of treatment, the global resistant hypertension treatment market can be classified into diuretic therapy, combination therapy, mineralocorticoid receptor antagonists, and others. Based on end-user, the global resistant hypertension treatment market can be categorized into hospital pharmacy, retail pharmacy, and online pharmacy. In terms of region, the global resistant hypertension treatment market can be divided into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is expected to dominate the global resistant hypertension treatment market due to availability of advanced medications in the region. Awareness regarding the disease is another factor boosting the resistant hypertension treatment market in North America. The resistant hypertension treatment market in Asia Pacific is anticipated to expand at a high growth rate due to increase in prevalence of the disease in the region. In Middle East & Africa, owing to unawareness about the disease in the underdeveloped countries such as Turkey, Cyprus, Syria, Lebanon, Iraq, etc. the resistant hypertension treatment market is expanding in the region.
Request for Analysis of COVID19 Impact on Resistant Hypertension Treatment Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=41111
Global Resistant Hypertension Treatment Market: Key Players

Key players operating in the global resistant hypertension treatment market are Johnson & Johnson Services, Inc., GlaxoSmithKline plc, Novartis AG, Pfizer Inc., Sanofi, F. Hoffmann-La Roche Ltd., and Amgen Inc., among others.
Pre-Book Resistant Hypertension Treatment Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=41111<ype=S

Contact
Transparency Market Research,
90 State Street, Suite 700,
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com/

About Us
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of analysts, researchers, and consultants, uses proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

This release was published on openPR.